The Prague Post - US study highlights success story of HPV vaccination

EUR -
AED 4.23719
AFN 80.135834
ALL 97.798467
AMD 439.918372
ANG 2.064799
AOA 1056.846409
ARS 1360.720244
AUD 1.777509
AWG 2.079657
AZN 1.96193
BAM 1.952774
BBD 2.319306
BDT 140.372501
BGN 1.957511
BHD 0.433329
BIF 3420.200601
BMD 1.153762
BND 1.475314
BOB 7.937701
BRL 6.396923
BSD 1.14872
BTN 98.846843
BWP 15.440077
BYN 3.759175
BYR 22613.741343
BZD 2.307425
CAD 1.567634
CDF 3319.374037
CHF 0.936589
CLF 0.02819
CLP 1068.414555
CNY 8.28586
CNH 8.293676
COP 4771.406987
CRC 579.002869
CUC 1.153762
CUP 30.574701
CVE 110.094415
CZK 24.809301
DJF 204.553057
DKK 7.458935
DOP 67.844878
DZD 150.02854
EGP 57.436382
ERN 17.306435
ETB 154.970782
FJD 2.593946
FKP 0.85007
GBP 0.851719
GEL 3.161735
GGP 0.85007
GHS 11.831668
GIP 0.85007
GMD 81.350521
GNF 9953.577519
GTQ 8.827323
GYD 240.327627
HKD 9.056198
HNL 29.980547
HRK 7.534872
HTG 150.646582
HUF 402.831494
IDR 18805.518075
ILS 4.153792
IMP 0.85007
INR 99.436426
IQD 1504.76845
IRR 48573.393545
ISK 144.001307
JEP 0.85007
JMD 183.915035
JOD 0.818026
JPY 166.746331
KES 148.410047
KGS 100.896972
KHR 4605.863487
KMF 492.083374
KPW 1038.386074
KRW 1578.52003
KWD 0.353305
KYD 0.957217
KZT 589.187089
LAK 24784.597729
LBP 102923.126693
LKR 343.947074
LRD 229.744025
LSL 20.672569
LTL 3.40676
LVL 0.697899
LYD 6.276275
MAD 10.502826
MDL 19.67152
MGA 5186.963107
MKD 61.439803
MMK 2422.55778
MNT 4132.43735
MOP 9.286811
MRU 45.60334
MUR 52.507446
MVR 17.773667
MWK 1991.813802
MXN 21.865408
MYR 4.898299
MZN 73.782996
NAD 20.672569
NGN 1779.608917
NIO 42.274498
NOK 11.43964
NPR 158.154948
NZD 1.917363
OMR 0.443343
PAB 1.14872
PEN 4.146176
PGK 4.798565
PHP 64.714144
PKR 325.655117
PLN 4.270166
PYG 9165.798137
QAR 4.190307
RON 5.019678
RSD 117.018686
RUB 91.852174
RWF 1658.729896
SAR 4.330755
SBD 9.630905
SCR 16.394893
SDG 692.823564
SEK 10.97093
SGD 1.480163
SHP 0.906676
SLE 25.440586
SLL 24193.823059
SOS 656.482819
SRD 43.29833
STD 23880.550451
SVC 10.051426
SYP 15001.047614
SZL 20.65899
THB 37.493823
TJS 11.601824
TMT 4.038168
TND 3.398934
TOP 2.702225
TRY 45.423733
TTD 7.78993
TWD 34.05944
TZS 2969.399091
UAH 47.647972
UGX 4139.585956
USD 1.153762
UYU 47.226825
UZS 14595.385312
VES 117.876459
VND 30084.352323
VUV 137.415593
WST 3.021918
XAF 654.942206
XAG 0.031816
XAU 0.000335
XCD 3.1181
XDR 0.814538
XOF 654.942206
XPF 119.331742
YER 280.767965
ZAR 20.727577
ZMK 10385.260948
ZMW 27.769972
ZWL 371.510994
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

US study highlights success story of HPV vaccination
US study highlights success story of HPV vaccination / Photo: PHILIPPE LOPEZ - AFP/File

US study highlights success story of HPV vaccination

A new study published Thursday by researchers at the US Centers for Disease Control and Prevention (CDC) highlights the powerful impact of the human papillomavirus (HPV) vaccine, first approved in 2006, in preventing precancerous lesions detected through cervical screening.

Text size:

HPV is the most common sexually transmitted infection, and certain strains can lead to cervical, vulvar, vaginal, and other cancers later in life. Each year, around 14 million Americans contract HPV, and the virus is responsible for approximately 10,800 cases of cervical cancer annually.

Since 2008, the CDC's Human Papillomavirus Vaccine Impact Monitoring Project has tracked trends in precancerous cervical lesions to evaluate the vaccine's effectiveness.

The findings are striking. Among women aged 20–24 screened for cervical cancer between 2008 and 2022, rates of moderate-to-high-risk precancerous lesions dropped by about 80 percent.

For women aged 25–29, the decline was 37 percent -- a smaller reduction the researchers attributed to many in this age group receiving the vaccine later in life as part of a "catch-up" vaccination effort, which is less effective.

In the US, the HPV vaccine was first approved in 2006 for girls and women, with boys and men added to the recommendations in 2011. Today, the CDC recommends routine HPV vaccination for boys and girls ages 11–12 to prevent infections that can lead to cancer later in life.

HPV includes over 200 different strains, some of which cause genital warts. Two particular strains -- 16 and 18 -- are classified as high-risk for cancer.

While cervical cancer is treatable if caught early, it is still responsible for around 4,400 US deaths per year.

The US Preventive Services Task Force recommends women ages 21 to 65 receive a Pap smear test once every three years and that women over 30 get high-risk HPV test every five years.

"The data are consistent with a considerable impact from the US HPV vaccination program on cervical precancers, with the largest decreases in the youngest age group for which benefit of vaccination would first be observed," wrote the authors in the CDC's Morbidity and Mortality Weekly Report.

They added that as vaccinated women age, further declines in cervical precancers are expected in older groups.

One limitation of the study was that individual vaccination status was not recorded, meaning the study could not directly confirm causality. However, the authors noted that "no other plausible explanations" have been identified for the sharp decline in precancers.

The study's positive findings come as outspoken anti-vaccine advocate Robert F. Kennedy Jr. begins his tenure as US health secretary.

Under his leadership, the Food and Drug Administration abruptly canceled a scheduled meeting with experts on Wednesday to discuss the development of next year's flu vaccines.

J.Simacek--TPP